MedTrace Logo

Liquid Biopsy for Early Non-small Lung Cancer Detection

NCT05462795 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 171

Last updated 2024-12-16

No results posted yet for this study

Summary

This clinical trial will assess the performance of a liquid biopsy assay to identify cancer in indeterminant pulmonary nodules identified by CT screening of high-risk individuals and evaluate the capability of the liquid biopsy assay to monitor response to surgical resection.

Conditions

  • Non Small-cell Lung Cancer

Interventions

DIAGNOSTIC_TEST

Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule

10 cc of blood is collected at one time point, which is prior to biopsy procedure

DIAGNOSTIC_TEST

Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection

10 cc of blood is collected at three time points: 1) before surgery; 2) 4-6 weeks post surgery; and 3) 6 months post surgery

DIAGNOSTIC_TEST

Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer

10 cc of blood is collected at one time point

DIAGNOSTIC_TEST

Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease

30 cc of blood is collected at one time point

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Arizona

    lead OTHER

Principal Investigators

  • Linda Garland, MD · University of Arizona

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-02
Primary Completion
2024-03-22
Completion
2024-03-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05462795 on ClinicalTrials.gov